Sutro Biopharma (STRO) Assets Average (2018 - 2025)

Sutro Biopharma (STRO) has 8 years of Assets Average data on file, last reported at $191.7 million in Q4 2025.

• For the quarter ending Q4 2025, Assets Average fell 54.29% year-over-year to $191.7 million; the trailing twelve-month figure through Dec 2025 stood at $191.7 million (down 54.29% YoY), and the FY2025 full-year result was $280.5 million, down 34.61% from the prior year.
• Assets Average fell to $191.7 million in Q4 2025, from $236.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $470.4 million in Q3 2024 to a low of $191.7 million in Q4 2025.
• A 5-year average of $373.1 million and a median of $379.4 million in 2021 frame the typical range for Assets Average.
• Across the five-year window, Assets Average soared 142.6% in 2021 and slumped 54.29% in 2025, its largest moves.
• Tracing STRO's Assets Average over 5 years: stood at $356.4 million in 2021, then climbed by 13.29% to $403.8 million in 2022, then gained by 11.74% to $451.2 million in 2023, then retreated by 7.03% to $419.5 million in 2024, then tumbled by 54.29% to $191.7 million in 2025.
• Business Quant data shows STRO's Assets Average at $191.7 million in Q4 2025, $236.0 million in Q3 2025, and $291.9 million in Q2 2025.